Kureha Valuation
Is 0K1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0K1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0K1 (€16.8) is trading above our estimate of fair value (€10.66)
Significantly Below Fair Value: 0K1 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0K1?
Key metric: As 0K1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0K1's PE Ratio? | |
|---|---|
| PE Ratio | 17.2x |
| Earnings | JP¥8.59b |
| Market Cap | JP¥147.33b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 6.7x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does 0K1's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.4x | ||
SIM0 SIMONA | 11.5x | n/a | €357.0m |
FPE3 Fuchs | 19.3x | 8.9% | €5.1b |
ACT AlzChem Group | 12.1x | 12.6% | €606.5m |
SDF K+S | 78.9x | 61.1% | €2.0b |
0K1 Kureha | 17.2x | 17.8% | €147.3b |
Price-To-Earnings vs Peers: 0K1 is good value based on its Price-To-Earnings Ratio (17.2x) compared to the peer average (30.4x).
Price to Earnings Ratio vs Industry
How does 0K1's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0K1 is expensive based on its Price-To-Earnings Ratio (17.2x) compared to the European Chemicals industry average (17.1x).
Price to Earnings Ratio vs Fair Ratio
What is 0K1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.2x |
| Fair PE Ratio | 14.1x |
Price-To-Earnings vs Fair Ratio: 0K1 is expensive based on its Price-To-Earnings Ratio (17.2x) compared to the estimated Fair Price-To-Earnings Ratio (14.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €16.80 | €19.00 +13.1% | 7.5% | €21.08 | €17.10 | n/a | 5 |
| Nov ’25 | €16.50 | €19.67 +19.2% | 7.5% | €21.83 | €17.71 | n/a | 5 |
| Oct ’25 | €17.70 | €19.67 +11.2% | 7.5% | €21.83 | €17.71 | n/a | 5 |
| Sep ’25 | €16.80 | €19.12 +13.8% | 8.5% | €21.35 | €16.71 | n/a | 5 |
| Aug ’25 | €17.40 | €18.47 +6.2% | 7.9% | €19.89 | €16.17 | n/a | 5 |
| Jul ’25 | €15.80 | €18.04 +14.2% | 7.8% | €19.68 | €16.00 | n/a | 5 |
| Jun ’25 | €16.50 | €17.51 +6.1% | 12.5% | €19.61 | €13.59 | n/a | 5 |
| May ’25 | €16.30 | €17.85 +9.5% | 12.8% | €20.13 | €13.95 | n/a | 5 |
| Apr ’25 | €16.20 | €18.51 +14.2% | 10.7% | €20.32 | €15.30 | n/a | 5 |
| Mar ’25 | €16.20 | €19.59 +20.9% | 6.7% | €20.62 | €17.39 | n/a | 4 |
| Feb ’25 | €17.50 | €19.82 +13.2% | 5.7% | €20.74 | €17.91 | n/a | 4 |
| Jan ’25 | €17.90 | €22.07 +23.3% | 14.0% | €26.81 | €18.49 | n/a | 4 |
| Dec ’24 | €17.33 | €22.03 +27.1% | 13.0% | €26.18 | €18.06 | n/a | 5 |
| Nov ’24 | €18.50 | €22.03 +19.1% | 13.0% | €26.18 | €18.06 | €16.50 | 5 |
| Oct ’24 | €17.33 | €22.29 +28.6% | 14.4% | €26.39 | €18.20 | €17.70 | 5 |
| Sep ’24 | €17.83 | €22.45 +25.9% | 14.2% | €26.68 | €18.40 | €16.80 | 5 |
| Aug ’24 | €17.50 | €22.45 +28.3% | 14.2% | €26.68 | €18.40 | €17.40 | 5 |
| Jul ’24 | €17.17 | €22.34 +30.2% | 14.7% | €26.50 | €18.28 | €15.80 | 5 |
| Jun ’24 | €17.67 | €22.55 +27.7% | 11.2% | €25.90 | €19.37 | €16.50 | 5 |
| May ’24 | €18.33 | €23.24 +26.8% | 8.6% | €25.97 | €19.87 | €16.30 | 5 |
| Apr ’24 | €19.17 | €24.94 +30.1% | 5.2% | €27.23 | €23.68 | €16.20 | 5 |
| Mar ’24 | €19.50 | €24.30 +24.6% | 3.7% | €25.63 | €23.30 | €16.20 | 5 |
| Feb ’24 | €19.33 | €26.02 +34.6% | 6.8% | €28.20 | €23.50 | €17.50 | 5 |
| Jan ’24 | €18.83 | €26.20 +39.1% | 4.8% | €27.89 | €24.54 | €17.90 | 5 |
| Dec ’23 | €22.50 | €26.91 +19.6% | 7.5% | €30.51 | €25.04 | €17.33 | 5 |
| Nov ’23 | €21.33 | €26.91 +26.1% | 7.5% | €30.51 | €25.04 | €18.50 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Ecora Resources
UK£162.5m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
HGR
UK£0.76
7D
-1.4%
1Y
-29.4%
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.91
7D
2.1%
1Y
-15.5%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-5.4%
1Y
-19.6%